Are Palpitations a Side Effect of Buspirone?
Yes, palpitations are a recognized side effect of buspirone, occurring in approximately 1% of patients in controlled clinical trials, though they remain relatively uncommon compared to other adverse effects.
Incidence and Clinical Significance
- Palpitations occur in approximately 1% of buspirone-treated patients according to FDA-approved labeling data from controlled clinical trials 1
- In a meta-analysis comparing dosing regimens, palpitations occurred significantly more frequently with buspirone 15 mg twice daily (5%) compared to 10 mg three times daily (1%), suggesting a potential dose-related effect 2
- This side effect is classified among cardiovascular adverse events but is generally considered a pharmacologic effect rather than a serious adverse reaction 1
Mechanism and Context
- Buspirone stimulates central sympathetic activity, which is reflected in increased peripheral neural sympathetic activity in healthy individuals 3
- The drug significantly increases circulating levels of noradrenaline and dopamine, which can manifest as palpitations through sympathetic nervous system activation 3
- These cardiovascular effects are similar to the transient pharmacologic effects seen with other medications that increase sympathetic tone, such as epinephrine (which commonly causes palpitations as an expected pharmacologic effect) 4, 5
Relative Frequency Compared to Other Side Effects
- Palpitations are much less common than the most frequent buspirone side effects: dizziness (12%), drowsiness (10%), nausea (8%), nervousness (5%), and headache (6%) 1
- The overall adverse event profile of buspirone remains favorable, with only approximately 10% of patients discontinuing treatment due to any adverse event during premarketing trials 1
- Cardiovascular disturbances are not among the primary reasons for drug discontinuation (which are mainly CNS disturbances at 3.4% and GI disturbances at 1.2%) 1
Clinical Management Considerations
- The twice-daily dosing regimen appears to carry higher risk for palpitations than three-times-daily dosing, despite equivalent total daily doses 2
- If palpitations occur, consider redistributing the total daily dose to more frequent, smaller doses (e.g., switching from 15 mg BID to 10 mg TID) 2
- Small but significant drops in systolic blood pressure and heart rate have been observed after buspirone ingestion, which may accompany or counterbalance the palpitation sensation 3
- Unlike psychostimulants (methylphenidate, dextroamphetamine), buspirone does not require avoidance in patients with underlying coronary artery disease or tachyarrhythmias, as it is not contraindicated in these populations 6
Important Caveats
- Palpitations should not be confused with serious cardiac arrhythmias, which are not characteristic of buspirone therapy 1
- The 2-4 week delay in therapeutic anxiolytic effect means that palpitations occurring early in treatment are not offset by anxiety reduction initially 7, 8
- Patients may misattribute anxiety-related palpitations to the medication, so careful assessment of temporal relationship to dosing is important 1